Table 3C.
Lymph node metastasis predictive model with CXC chemokines/receptors.
| Variable | Odds ratio | p-value | VIF | |
|---|---|---|---|---|
| PSA (Preoperative) | 1.04 (0.99–1.09) | 0.0553 | 1.070 | |
| Primary Gleason Score | 3.86 (1.38–10.8) | 0.0100 | 1.134 | |
| ELR+ Chemokine Receptor | CXCR1 | 0.85 (0.33–2.17) | 0.7350 | 1.096 |
| ELR+ Chemokine | CXCL5 | 0.03 (0–3.00) | 0.1420 | 1.141 |
| ELR− Chemokine Receptor | CXCR3 | 0.67 (0.31–1.43) | 0.3010 | 1.609 |
| ELR− Chemokine | CXCL10 | 3.47 (1.38–8.75) | 0.0083 | 1.650 |
| Multivariable Model 2: | ||||
| Lymph Node Stage (N0 or N1) = Primary Gleason Score + PSA (Preoperative) + CXCR1 + CXCL5 + CXCR3 + CXCL10 | ||||
| p-value < 0.001 | ||||
| AUC = 0.887 (0.803–0.950) | ||||
AUC, area under the curve; PSA, Prostate-Specific Antigen; VIF, Variance Inflation Factor.
Multivariate logistic regression analysis was performed using clinical information (preoperative PSA and primary Gleason score), one ELR+ CXC chemokine, one ELR− CXC chemokine, and the corresponding receptors of those with the highest AUC values by univariate analysis (CXCL5/CXCR1 and CXCL10/CXCR3; Model 2).